We also employed a small molecule inhibitor of CBFβ (AI-14-91), which disrupts its interaction with the RUNT domain of RUNX proteins and has been shown to affect the survival of AML but not normal cells [23, 40] (Supplementary Fig. S10H). Here, CBFB is linked to acute myeloid leukemia.